We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid POC Test for Diagnosis of Preeclampsia Could Prevent Unnecessary Hospitalization

By LabMedica International staff writers
Posted on 16 May 2022

Preeclampsia is a pregnancy disorder that can have devastating effects on the health of the mother and the unborn baby. More...

Affecting 5-8% of all pregnancies, it is a rapidly progressive and potentially deadly condition. A correct diagnosis of the pregnancy disorder is currently time-consuming and, in many cases, inaccurate. Now, a fast and precise point-of-care test for preeclampsia is being developed that would provide diagnostic certainty and at the same time, save healthcare costs.

MOMM Diagnostics (Basel, Switzerland) is developing a rapid test for preeclampsia that would offer unprecedented sensitivity at the point-of-care. MOMM develops high-sensitivity rapid diagnostic tests. Immediate information during pregnancy check-ups will help doctors to optimize treatment, reduce stress and anxiety for expectant mothers, save lives and reduce costs. The rapid test for preeclampsia will be based on the company’s technology that combines the commercial advantage of lateral flow immunoassays, with the sensitivity of ELISA, and reader simplicity similar to blood glucose meters.

Since pregnant women regularly go to medical check-ups, the test can be carried out at the gynecologist without the need to send blood samples to a specialized diagnostics lab. The rapid screening test for preeclampsia will also spare expectant mothers the long wait for lab results. This will save valuable time and enable treatment to be started quickly. By providing diagnostic certainty, the test would also eliminate the possibility of false positive results by conventional tests that can create unnecessary anxiety for pregnant women.

Related Links:
MOMM Diagnostics 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Lead author Professor Chamindie Punyadeera. (Image Credit: Griffith University)

Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules

Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.